Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423339 | 0.77 | KDM4E (0.80) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL22339125 | 0.74 | KDM4E (0.54) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL14991003 | 0.74 | KDM4E (0.54) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL243962 | 0.74 | KDM4E (0.54) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL243961 | 0.74 | KDM4E (0.54) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL8228389 | 0.74 | KDM4E (0.48) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL994469 | 0.73 | — | — | |
| SCHEMBL28349461 | 0.72 | KDM4E (0.52) | KDM4EMAPTUSP2ALDH1A1PKM | |
| SCHEMBL477197 | 0.72 | KDM4E (0.52) | KDM4EMAPTUSP2ALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL2592331 | 0.72 | KDM4E (0.52) | KDM4EMAPTUSP2ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-8450373-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-1799667-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-03-20 | — | — | EP | disclosed |
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | APPLERA CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7696250-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488848-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20040110805-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-06-10 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004043943-A1 | AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6689794-B2 | SUPPRESSING MATRIX METALLOPROTEINASE AND/OR AGGRECANASE ACTIVITY | PHARMACIA CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20040024024-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1385836-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20040010019-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-01-15 | — | — | US | disclosed |
| WO-2004000811-A1 | ARYLSULFONYLHYDROXAMIC ACID AND AMIDE DERIVATIVES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002092588-A2 | AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | KDM4E 994/4885MAPT 1614/4885USP2 444/4885 |
| US-20040110805-A1 | Aromatic sulfone hydroxamic acids and their use as protease inhibitors | MMP1, MMP7, MMP3 | KDM4E 853/4885MAPT 1453/4885USP2 1096/4885 |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | KDM4E 3408/4885MAPT 2656/4885USP2 1835/4885 |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | KDM4E 994/4885MAPT 1614/4885USP2 444/4885 |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | KDM4E 3408/4885MAPT 2656/4885USP2 1835/4885 |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | KDM4E 994/4885MAPT 1614/4885USP2 444/4885 |
| US-20040010019-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | MMP1, MMP3, MMP7 | KDM4E 784/4885MAPT 1413/4885USP2 1084/4885 |
| US-20040024024-A1 | Aromatic sulfone hydroxamates and their use as protease inhibitors | MMP1, MMP3, MMP7 | KDM4E 784/4885MAPT 1413/4885USP2 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.